First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
- Seven active clinical trials:
* First patients treated in four combination trials assessing TG4010 (lung cancer) or Pexa-Vec (liver cancer and other solid tumors)
- Two collaboration agreements signed with:
* Bristol-Myers Squibb, for a combination clinical trial of TG4010 (1st-line treatment of lung cancer)
* Servier, for a scientific collaboration to improve the production process for allogenic CAR-T cells
- Cash and cash equivalents as of June 30, 2017: ?43.9 million, financial visibility confirmed to the end of 2018
Strasbourg, France, September 13, 2017, 5:35 p.m. CET – Transgene (Euronext Paris: TNG), a biotechnology company focused on designing and developing viral-based immune-targeted therapies, today announced its financial results for the six-month period ended June 30, 2017, and reviews the progress of it products portfolio since the beginning of the year.
.../...
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer